Reading this on a mobile device? Try our optimized mobile version here:

December 17, 2012
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  Health Care & Policy 
  • FDA approves Ariad's Iclusig for rare leukemias
    Ariad Pharmaceuticals obtained accelerated FDA approval for Iclusig, or ponatinib, to treat patients with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. The drug, which was cleared three months ahead of schedule, inhibits certain proteins that promote cancer cell development. Iclusig will be sold with a boxed warning on its label about risk of blood clots and liver poisoning. Fox Business/Dow Jones Newswires (12/14), HealthDay News (12/14) LinkedInFacebookTwitterEmail this Story
  • EU backs approval of Alexza's agitation drug Adasuve
    Alexza Pharmaceuticals' investigational drug Adasuve was recommended for approval by a European Medicines Agency committee for use in controlling agitation in patients with bipolar disorders and schizophrenia. The drug, which also is being evaluated by the FDA, was recommended for use in hospitals with the supervision of a health care provider. Reuters (12/14) LinkedInFacebookTwitterEmail this Story
  • Advanced Cell seeks FDA OK for trial of stem cell-based platelets
    Advanced Cell Technology will seek regulatory approval for a clinical trial involving platelets made from patients' own adult cells reprogrammed as stem cells. The platelets could reduce the risk of resistance that comes with repeat infusions for the treatment of anemia, leukemia and other conditions. The trial could begin before 2014. The Wall Street Journal (12/13) LinkedInFacebookTwitterEmail this Story
  • Genetically altered T-cells subdue multiple myeloma
    Genetically engineered T-cells injected into 13 people with multiple myeloma improved each person's condition, so much so that all improved to some degree, with 10 nearing or reaching remission just three months after the injection. "The fact we got a response in all 13, you can't get better than that," said Adaptimmune CEO James Noble in Abingdon, England. His company developed the treatment. A team of University of Maryland researchers took T-cells -- which fight tumor cells -- from each patient, inserted engineered genes into the cells and re-injected them into the patients. New Scientist (12/11) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Food & Agriculture 
  Hot Topics 

Top five news stories selected by BIO SmartBrief readers in the past week.

  • Results based on number of times each story was clicked by readers.
  Industrial & Environmental 
  • Solazyme reaches algae-based oil production milestone
    Solazyme said it has achieved commercial-scale algae-based oil production at a fermentation plant owned by Archer Daniels Midland in Iowa. Solazyme made renewable oil in 132,000-gallon containers at the facility, the company said. "Solazyme's fermentations have reached a scale that, to our knowledge, is the highest level of any algae-based company in the world," said analyst Pavel Molchanov of Raymond James & Associates. Bloomberg Businessweek (12/14) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

Action is the antidote to despair."
--Joan Baez,
American singer

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information